BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.
Administration, Intravesical
Animals
Antineoplastic Agents
/ administration & dosage
BCG Vaccine
/ administration & dosage
Female
Humans
Immunity, Innate
/ drug effects
Immunotherapy
Inflammation Mediators
/ metabolism
Lymphocytes, Tumor-Infiltrating
/ drug effects
Membrane Proteins
/ immunology
Mice, Inbred C57BL
Radiation Dosage
T-Lymphocytes
/ drug effects
Tumor Microenvironment
/ immunology
Tumor-Associated Macrophages
/ drug effects
Urinary Bladder Neoplasms
/ immunology
Urothelium
/ drug effects
BCG
STING
T-cells
Trex-1
bladder cancer
innate immunity
interferon
macrophages
radiotherapy
tumor immune microenvironment
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
07
10
2021
received:
21
04
2021
accepted:
30
10
2021
pubmed:
4
11
2021
medline:
22
2
2022
entrez:
3
11
2021
Statut:
ppublish
Résumé
Radiation and bacillus Calmette-Guérin (BCG) instillations are used clinically for treatment of urothelial carcinoma, but the precise mechanisms by which they activate an immune response remain elusive. The role of the cGAS-STING pathway has been implicated in both BCG and radiation-induced immune response; however, comparison of STING pathway molecules and the immune landscape following treatment in urothelial carcinoma has not been performed. We therefore comprehensively analyzed the local immune response in the bladder tumor microenvironment following radiotherapy and BCG instillations in a well-established spontaneous murine model of urothelial carcinoma to provide insight into activation of STING-mediated immune response. Mice were exposed to the oral carcinogen, BBN, for 12 weeks prior to treatment with a single 15 Gy dose of radiation or three intravesical instillations of BCG (1 × 10
Identifiants
pubmed: 34731491
doi: 10.1002/path.5830
pmc: PMC8738146
mid: NIHMS1753304
doi:
Substances chimiques
Antineoplastic Agents
0
BCG Vaccine
0
Inflammation Mediators
0
Membrane Proteins
0
STING1 protein, human
0
Sting1 protein, mouse
0
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
223-234Subventions
Organisme : NCI NIH HHS
ID : F30 CA260765
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI155346
Pays : United States
Informations de copyright
© 2021 The Pathological Society of Great Britain and Ireland.
Références
Nat Rev Urol. 2014 Mar;11(3):153-62
pubmed: 24492433
Sci Rep. 2016 Jan 25;6:19740
pubmed: 26804478
Cancer Immunol Immunother. 2017 Jun;66(6):705-716
pubmed: 28243692
J Infect Dis. 2020 Mar 16;221(7):1048-1056
pubmed: 30901058
Nat Med. 2015 Apr;21(4):401-6
pubmed: 25730264
Oncotarget. 2016 Feb 9;7(6):6424-35
pubmed: 26824503
Sci Rep. 2017 Feb 08;7:39858
pubmed: 28176788
World J Urol. 2021 May;39(5):1331-1343
pubmed: 32915313
Oncoimmunology. 2013 Sep 1;2(9):e25962
pubmed: 24327938
Methods Mol Biol. 2018;1655:155-167
pubmed: 28889385
Int J Cancer. 2012 Mar 1;130(5):1109-19
pubmed: 21480223
Nat Rev Clin Oncol. 2019 Dec;16(12):729-745
pubmed: 31243334
Cell Rep. 2015 May 19;11(7):1018-30
pubmed: 25959818
Oncotarget. 2016 Jun 28;7(26):39916-39930
pubmed: 27221038
Mucosal Immunol. 2013 Nov;6(6):1041-53
pubmed: 24064671
Transl Oncol. 2019 Mar;12(3):485-492
pubmed: 30594037
Hum Pathol. 2019 Jul;89:24-32
pubmed: 31026471
Semin Radiat Oncol. 2020 Apr;30(2):129-138
pubmed: 32381292
Exp Ther Med. 2015 Jan;9(1):162-166
pubmed: 25452795
Cancer Immunol Res. 2018 Apr;6(4):422-433
pubmed: 29472271
Cancer Immunol Res. 2017 Nov;5(11):992-1004
pubmed: 28970196
Adv Exp Med Biol. 2014;772:147-65
pubmed: 24272358
Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):769-76
pubmed: 24064321
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Cancer Res. 2006 Aug 15;66(16):8250-7
pubmed: 16912205
Eur Urol. 2018 Nov;74(5):540-544
pubmed: 30033046
Oncoimmunology. 2016 Feb 18;5(5):e1134412
pubmed: 27467953
Cancer Immunol Immunother. 2009 Aug;58(8):1245-55
pubmed: 19139883
J Innate Immun. 2014;6(2):152-8
pubmed: 24192057
Oncotarget. 2020 Jul 28;11(30):2930-2955
pubmed: 32774773
Cancer Res. 2011 Apr 1;71(7):2488-96
pubmed: 21300764
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
J Urol. 1993 Sep;150(3):1018-23
pubmed: 8102183
Dev Dyn. 2017 Apr;246(4):336-343
pubmed: 28109014
Clin Cancer Res. 2020 Feb 15;26(4):882-891
pubmed: 31712383
Immunity. 2014 Nov 20;41(5):830-42
pubmed: 25517615
Eur Urol Focus. 2019 May;5(3):457-466
pubmed: 29366854
Cancer Immunol Res. 2017 Jul;5(7):594-603
pubmed: 28588015
Cancer Immunol Immunother. 2003 Aug;52(8):481-6
pubmed: 12707736
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
Urol Oncol. 2011 Jan-Feb;29(1):58-65
pubmed: 19837616
Am J Cancer Res. 2015 Oct 15;5(11):3276-85
pubmed: 26807310
Cell Rep. 2016 Jan 12;14(2):282-97
pubmed: 26748708
J Immunother Cancer. 2018 Jun 4;6(1):46
pubmed: 29866197
Int J Cancer. 2001 Jun 1;92(5):697-702
pubmed: 11340575
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
PLoS One. 2010 Dec 17;5(12):e15263
pubmed: 21179419
J Immunol. 2014 Dec 15;193(12):6124-34
pubmed: 25385820